ArticleBlood2011
Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Direct recognition of an intact foreign protein by an αβ T cell receptor.Nature communications · 2024Article
- Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin.PloS one · 2024Article
- MHC-independent αβT cells: Lessons learned about thymic selection and MHC-restriction.Frontiers in immunology · 2022Review
- Enzymatic Noncovalent Synthesis.Chemical reviews · 2020Review
- Structure of MHC-Independent TCRs and Their Recognition of Native Antigen CD155.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- MHC Restriction: Where Are We Now?Viral immunology · 2020Article
- Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.Frontiers in immunology · 2020Review
- Understanding the drivers of MHC restriction of T cell receptors.Nature reviews. Immunology · 2018Review
- Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients.Oncotarget · 2017Article
- Enzyme-Instructed Self-Assembly of Small D-Peptides as a Multiple-Step Process for Selectively Killing Cancer Cells.Journal of the American Chemical Society · 2016Article
- The T cell antigen receptor: the Swiss army knife of the immune system.Clinical and experimental immunology · 2015Review
- Enzyme-instructed self-assembly: a multistep process for potential cancer therapy.Bioconjugate chemistry · 2015Review
- Cell transfer therapy for cancer: past, present, and future.Journal of immunology research · 2014Review
- Article
- MHC restriction is imposed on a diverse T cell receptor repertoire by CD4 and CD8 co-receptors during thymic selection.Trends in immunology · 2012Article
- Raising the bar: the curative potential of human cancer immunotherapy.Science translational medicine · 2012Review
- Article
- Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
During an analysis of T-cell responses against human renal cell carcinoma (RCC), we identified a CD4(+) T-cell line that showed TCR-mediated recognition and lysis of nearly all RCC lines regardless of MHC type. We have now elucidated the nature of the ligand for this α/β TCR, and it contains no MHC-related moiety and does not involve classic peptide processing. First, matrix metalloproteinase 14 (MMP14) expressed on RCC cells releases membrane-bound TRAIL expressed by the T cell; then, soluble TRAIL binds to its receptor DR4 (TRAIL-R1), which is expressed on tumor cells, and this TRAIL-DR4 complex is recognized by the TCR through a complementarity-determining region 3α (CDR3α)-mediated interaction. Direct and specific antigen-TCR interaction was demonstrated when the immobilized recombinant TRAIL/DR4 complex stimulated the TCR. In addition, amino acid substitutions in the CDR3α of the TCR either obliterated or enhanced target-specific recognition. This description of the molecular nature of a non-MHC target structure recognized by a naturally occurring α/β TCR not only broadens our concept of what the TCR can recognize, but also raises the question of whether such a T cell could be of clinical utility against RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.